Immuron (IMRN) Interest & Investment Income (2017 - 2024)
Immuron (IMRN) posted quarterly Interest & Investment Income of $35.3 billion for Q4 2024, up 23001335.32% year-over-year from N/an in Q1 2024, and up 23001335.32% quarter-over-quarter from $153508.0 in Q4 2023.
Immuron (IMRN) Interest & Investment Income (2017 - 2024) Analysis & Trends
Immuron's Interest & Investment Income history runs 8 years deep, the most recent figure standing at $35.3 billion for Q4 2024.
- In Q4 2024, Interest & Investment Income rose 23001335.32% year-over-year to $35.3 billion; the TTM figure through Dec 2024 stood at $35.3 billion (up 16998463.83% YoY), while the FY2025 annual figure was $88058.7, down 59.03% from the prior year.
- Interest & Investment Income for Q4 2024 stood at $35.3 billion, up from $153508.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $35.3 billion in Q4 2024, with the low at $63.29 in Q4 2020.
- The 5-year median for Interest & Investment Income is $54072.0 (2022), against an average of $7.1 billion.
- The sharpest annual moves came in 2021 and 2024: Interest & Investment Income grew 19.66% in 2021, then jumped 23001335.32% in 2024.
- Immuron's Interest & Investment Income stood at $63.29 in 2020, then rose by 19.66% to $75.73 in 2021, then soared by 71296.7% to $54072.0 in 2022, then surged by 183.9% to $153508.0 in 2023, then surged by 23001335.32% to $35.3 billion in 2024.
- Business Quant data shows IMRN's Interest & Investment Income at $35.3 billion in Q4 2024, $153508.0 in Q4 2023, and $54072.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35.31 Bn |
| Dec 31, 2023 | 153,508.00 |
| Dec 31, 2022 | 54,072.00 |
| Dec 31, 2021 | 75.73 |
| Dec 31, 2020 | 63.29 |
| Dec 31, 2019 | 2.59 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2017 | 33.51 |